Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015

Antineoplastic agents, Health-related quality of life, Clinical efficacy, Drug approvals, Patient-relevant outcomes

The study investigates cancer drugs approved by the European Medicines Agency (EMA) that initially lack Health-related Quality of Life (HRQoL) information. Data was collected for cancer indications approved between January 2009 and October 2015, using sources like the EMA website, clinical…

Feb 23^rd • 12 mins read

Medical affairs: The power behind redefining commercialization

Medical affairs commercialization, integrating science in pharma, redefining medical affairs roles, strategic medical affairs leadership, early engagement with payers, pharmaceutical commercialization strategies, upskilling in medical affairs, medical aff

In March 2024, Envision Pharma Group held a Medical Affairs Professional Society (MAPS) Americas roundtable with leaders discussing the role of science in commercialization strategies and the importance of integrating robust scientific understanding into the commercial journey. Envision revisite…

Aug 2^nd • 3 mins read

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

ASCO VF, ESMO MCBS, gastrointestinal malignancies, anticancer drugs

Drugs approved between 2006 and 2017 were analyzed. Clinical benefit was measured using ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework. 16 GI cancer drugs received FDA approval for 24 indications, including various drug classes such as monoclonal antibodies, oral targeted …

Mar 7^th • 8 mins read